Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fork in the road

Following their setback with tariquidar last week, QLT Inc. and partner Xenova Group plc are faced with very different dilemmas, as the former has cash but lacks

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE